EP0900202A1 - Esters d'amide de 3-alcoxypyridine-2-acide carboxylique, leur preparation et leur utilisation comme medicaments - Google Patents

Esters d'amide de 3-alcoxypyridine-2-acide carboxylique, leur preparation et leur utilisation comme medicaments

Info

Publication number
EP0900202A1
EP0900202A1 EP96914152A EP96914152A EP0900202A1 EP 0900202 A1 EP0900202 A1 EP 0900202A1 EP 96914152 A EP96914152 A EP 96914152A EP 96914152 A EP96914152 A EP 96914152A EP 0900202 A1 EP0900202 A1 EP 0900202A1
Authority
EP
European Patent Office
Prior art keywords
formula
compounds
radical
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96914152A
Other languages
German (de)
English (en)
Inventor
Klaus Weidmann
Karl-Heinz Baringhaus
Georg Tschank
Martin Bickel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of EP0900202A1 publication Critical patent/EP0900202A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the invention relates to 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and their use for inhibiting collagen biosynthesis and their use as medicaments for the treatment of fibrotic diseases.
  • Inhibitors of prolyl hydroxylase are therefore suitable substances in the therapy of diseases in which the deposition of collagens contributes significantly to the clinical picture. These include a. Fibrosis of the lungs, liver and skin (scleroderma and scarring after burns, injuries and surgical interventions) and atherosclerosis.
  • N-oxalylglycines as inhibitors of prolyl-4-hydroxylase are known from J. Med. Chem. 1 992, 35, 2652-2658 (Cunliffe et al.) And EP-A-0 457 1 63.
  • the object was therefore to provide compounds which are distinguished by a particularly high in vivo and / or in vitro activity, in particular when used systemically and / or locally.
  • 3-alkoxypyridine-2-carboxylic acid ester amides of the formula I are particularly potent inhibitors of collagen biosynthesis.
  • the compounds according to the invention represent a selection from the compounds described in EP-A-0 650 960. In comparison to the compounds mentioned in the European patent application, they are distinguished by a particularly high in vivo and in vitro activity, especially when used systemically and / or locally against fibrotic diseases. These include, for example, fibroids of the lungs, liver, kidney, heart, eye and skin, and in the case of atherosclerosis.
  • the compounds of the formula I lead to a strong inhibition of collagen biosynthesis in the most varied of cells (e.g. normal human skin fibroblasts, primary fat storage cells from rat liver, rat liver epithelial cells and in organ cultures of calvaria).
  • cells e.g. normal human skin fibroblasts, primary fat storage cells from rat liver, rat liver epithelial cells and in organ cultures of calvaria.
  • the compounds of the formula I are, for example, suitable for local use to prevent / reduce scarring after surgical interventions on the human body and for local use in the postoperative treatment of eye diseases, for example the postoperative treatment of glaucoma and in radiation-induced or chemotherapy-induced Fibrosis, especially on the lungs.
  • the compounds according to the invention are ester prodrugs of the corresponding carboxylic acids of the formula I, in which B denotes a carboxyl group.
  • the compounds of the formula I are cleaved in the living organism (in vivo) and in cell cultures (in vitro) to give compounds of the formula I in which B denotes a carboxyl group or its salts.
  • the compounds of the formula I After application of the compounds of the formula I, they inhibit collagen biosynthesis, which can be observed in vivo and in vitro, the compounds of the formula I in which B denotes a carboxyl group or its salts being formed. These compounds inhibit prolyl 4-hydroxylase and therefore lead to an inhibition of collagen biosynthesis.
  • R 1 , R 2 and R 3 are hydrogen, R 4 (C r C 6 ) alkyl,
  • A represents a -CH 2 group in which a hydrogen can be replaced by a methyl group
  • G represents the remainder of an alcohol GOH, including the physiologically active salts.
  • R ⁇ R 2 and R 3 are hydrogen
  • A represents a -CH 2 group in which a hydrogen can be replaced by a methyl group
  • G is a branched or unbranched or cyclic (C 1 -C 4 alkyl) radical, or a branched or unbranched or cyclic (C 2 -C 20 ) alkenyl radical, a corresponding (C 2 -C 20 ) alkynyl radical, means a corresponding (C 4 -C 20 ) alkeninyl residue or a retinyl residue, where the residues can each contain one or more multiple bonds, or denotes a phenylalkyl residue, the above residues in particular one or more substituents from the series Hydroxy, halogen, cyano, trifluoromethyl, carboxy, (C, -C 1 2 ) alkyl, (C 3 -C 8 ) cycloalkyl, (C 5 -C 8 ) cycloalkenyl, (C r C 1 2 ) alkoxy , (C r C 1 2 ) -alkoxy- (C r C 12 )
  • R 1 , R 2 and R 3 are hydrogen
  • A represents a -CH 2 group in which a hydrogen atom can be replaced by a methyl group
  • G is a branched or unbranched or cyclic aliphatic (C r C 18 ) alkyl radical, a (C 3 -C 8 ) cycloalkyl (C r C 8 ) alkyl radical, a branched or unbranched (C 2 -C 1 8 ) -Alkenyl radical, such as, for example, a geranyl, farnesyl or retinyl radical, or a corresponding (C 2 -C 18 ) -alkynyl radical, a benzyl, phenethyl, phenylpropyl or phenylbutyl radical,
  • radicals are a substituent from the series hydroxy, (C r C 4 ) alkoxy, (C r C 6 ) alkylcarbonyloxy, (C 3 -C 8 ) cycloalkylcarbonyloxy, benzoyloxy or phenyl (C r C 4 ) - alkylcarbonyloxy, including the physiologically active salts.
  • R 1 , R 2 and R 3 are hydrogen
  • A represents a -CH 2 group in which a hydrogen atom can be replaced by a methyl group
  • G is a branched or unbranched or cyclic aliphatic (C i "-C 8 ) alkyl radical, a (C 3 -C 8 ) cycloalkyl (C, -C 4 ) alkyl radical, a branched or unbranched (C 2 - C 18 ) alkenyl, benzyl, phenethyl, phenylpropyl or phenylbutyl the physiologically active salts.
  • R 1 , R 2 and R 3 are hydrogen
  • A represents a -CH 2 group in which a hydrogen is replaced by a
  • Methyl group can be replaced, and B means -CO 2 G, wherein
  • G is a branched or unbranched (C 1 -C 18 ) alkyl or
  • (C 2 -C 18 ) alkenyl radical means, including the physiologically active salts.
  • R 1 , R 2 and R 3 are hydrogen
  • A is a -CH 2 group
  • G is a branched or unbranched (C 1 -C l 8) alkyl or (C 2 -C 18) -
  • Alkenyl radical means, including the physiologically active salts.
  • R 1 , R 2 and R 3 are hydrogen
  • A is a -CH 2 group
  • G is a linear (C 1 -C l 8) -alkyl radical, including the physiologically active salts. Particularly preferred are those compounds of formula I in which G is a linear (C r C 1 6) alkyl radical, including the physiologically active salts.
  • the invention further comprises salts of the compounds of the general formula I.
  • Salt binding with acidic reagents can take place on the pyridine N atom.
  • Reagents used are, for example, toluenesulfonic acid, methanesulfonic acid, HCl, H 2 SO 4 , H 3 PO 4 and medicaments which contain an acidic group.
  • the invention relates to the compounds of the general formula I and the physiologically tolerable salts for use in inhibiting collagen biosynthesis, in particular in various cells.
  • the invention relates to the compounds of general formula I and the physiologically acceptable salts for use in inhibiting prolyl 4-hydroxylase in vivo and in vitro.
  • the invention further relates to the compounds of general formula I and the physiologically tolerable salts for use in fibrotic diseases of the lungs, liver, kidney, heart, eye and skin.
  • the compounds can also be used in atherosclerosis. Systemic and / or local applications are used here.
  • the invention relates to compounds of the general formula I and the physiologically tolerable salts for topical use, in particular as inhibitors of collagen biosynthesis, as antifibrotic active substances and in the case of disease forms which result from an increased formation of Connective tissue (collagen) are caused.
  • These include the applications for avoiding / reducing scarring after surgical interventions on the human body and in the postoperative treatment of eye surgery, for example in glaucoma surgery and in radiation-induced or chemotherapy-induced fibrosis, in particular on the lungs.
  • the invention relates to the compounds of general formula I for use as medicaments.
  • the invention relates to compounds of the formula I for topical use in fibroids of the skin, lungs and eyes, in particular for postoperative treatment of glaucoma.
  • the invention further relates to a process for the preparation of compounds of the general formula I.
  • the compounds of the formula IV are esterified with an alcohol GOH; or iii) the compounds of the formula V are alkylated with R 4 X, where X is a leaving group, in particular halogen, -OSO 2 Me, -OSO 2 phenyl and others.
  • reaction i1 Suitable methods for amide formation (reaction i1) are the methods of carbonyl activation and the condensation reactions known from peptide chemistry.
  • the substances known to the person skilled in the art can be used as reagents for carboxylic acid activation.
  • the activated derivatives of the compounds of the formula II are reacted in situ with the amide derivatives of the formula III.
  • a suitable condensing agent is, for example, the combination of N, N'-dicyclohexylcarbodiimide / N-hydroxy-1 H-benzotriazole and N-ethylmorpholine.
  • Suitable solvents are dichloromethane, carbon tetrachloride, butyl acetate, ethyl acetate, toluene, tetrahydrofuran, dimethoxyethane, 1,4-dioxane, acetonitrile, N, N-dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide, nitromethane and / or pyridine.
  • the compounds of formula I according to the invention have valuable pharmacological properties and, in particular, show antifibrotic activity.
  • Collagen content of subcutaneously implanted "cotton pellets" or polyvinyl sponges e.g. Boyle, E., Mangan, F.R. , Br. J. Ep. Pathnol. 61: 351-60, 1980; and
  • Lung collagen content after radiation-induced or chemically induced fibrosis radiate. e.g. Ward, H.E. et al., Res., 1 36, 1 5-21, 1993, and Santana, A. et al. At the. J. Respir. Cell. Mol. Biol. 1 3: 34-44, 1995.
  • Calvaries are prepared from 1 5 day old chicken embryos and washed for 3 min at 37 ° C in Hanks' balanced salt solution minimum essential medium Eagle (HMEM, BioWhittaker, Walkersville, MD, USA). 4 calvaries each are incubated in glass vessels with 1.5 ml of HMEM with the addition of 2 mM glutamine and 1 ⁇ O [U- 14C] Prol ⁇ n and various inhibitor concentrations at 37 ° C. for 2.5 h. The incubation is ended by placing the sample vessels in ice. The medium is removed and the calvaries are briefly washed with 1 ml bidest H 2 O.
  • HMEM Hanks' balanced salt solution minimum essential medium Eagle
  • the amino acids are then derivatized for 20 min at room temperature in a solution of ethanol / triethylamine / phenyl isothiocyanate / H 2 O 7: 1: 1: 1 (v: v: v: v) and dried again.
  • the samples are dissolved in 1 50 ⁇ l of a phosphate buffer (5 mM Na 2 HPO 4 , pH 7.4 / acetonitrile 95: 5 (v: v)) and centrifuged at 10,000 g for 5 min. 50 ⁇ ⁇ are used for analysis.
  • HPLC chromatography is carried out on a C 1 8 reverse phase column Ultrasphere ODS 3 ⁇ m, 4.6 nim x 7.5 cm (Beckman) at 50 ° C with the following gradient system:
  • the compounds of the formula I can be used as medicaments in the form of pharmaceutical preparations which they may contain with compatible pharmaceutical carriers.
  • the compounds can be used as remedies e.g. find use in the form of pharmaceutical preparations which mix these compounds with a pharmaceutical, organic or inorganic carrier suitable for enteral, percutaneous, parenteral and inhalation administration, e.g. Contain water, gum arabic, gelatin, milk sugar, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, petroleum jelly etc.
  • they can be administered orally in doses of 0.1 to 25 mg / kg / day, preferably 1 to 5 mg / kg / day or parenterally in doses of 0.01 to 5 mg / kg / day, preferably 0.01 to 2.5 mg / kg / day, in particular 0.5 to 1.0 mg / kg / day.
  • the dosage can also be increased in severe cases. In many cases, however, lower doses are sufficient.
  • These figures refer to an adult weighing approximately 75 kg.
  • the 3-methoxypyridine-2-carboxylic acid used as starting compound in the following examples was obtained starting from 4-chloro-3-methoxy-2-methylpyridine, which was obtained from maltol ( cf. EP-A-0 208 452 and EP- A-0 304 732).
  • substituted pyridine-2-carboxylic acid (glycylester) amides are referred to as substituted pyridine-2-carboxylic acid (glycylester) amides.
  • Example 7 3-methoxypyridine-2-carboxylic acid N - (((1-nonyloxy) carbonyl) methyl) amide
  • Example 8 3-methoxypyridine-2-carboxylic acid N - (((1-decylox ⁇ ) carbonyl) methyl) amide
  • Example 1 3-methoxypyridine-2-carboxylic acid N - (((1-propyloxy) carbonyl) methyl) amide
  • Example 1 (3-Methoxypyridine-2-carboxylic acid N - (((2-propyloxy) carbonyl) methyl) amide
  • Example 13 3-methoxypyridine-2-carboxylic acid N - (((1-tridecyloxy) carbonyl) methyl) amide
  • Example 1 3-Methoxypyridine-2-carboxylic acid N - (((4-heptyloxy) carbonyl) methyl) amide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne des esters d'amide de 3-alcoxypyridine-2-acide carboxylique de la formule (I) dans laquelle R?1, R2 et R3¿ désignent hydrogène, R4 désigne alkyle(C¿1?-C6), A désigne un groupe -CH2 dans lequel un hydrogène peut être remplacé par un groupe méthyle, et B désigne -CO2G, G désignant le reste d'un alcool GOH, y compris les sels à action physiologique. L'invention concerne leur préparation, leur utilisation pour inhiber la biosynthèse du collagène, ainsi que leur utilisation comme médicaments pour traiter des affections fibreuses.
EP96914152A 1996-04-30 1996-04-30 Esters d'amide de 3-alcoxypyridine-2-acide carboxylique, leur preparation et leur utilisation comme medicaments Withdrawn EP0900202A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1996/001793 WO1997041103A1 (fr) 1996-04-30 1996-04-30 Esters d'amide de 3-alcoxypyridine-2-acide carboxylique, leur preparation et leur utilisation comme medicaments

Publications (1)

Publication Number Publication Date
EP0900202A1 true EP0900202A1 (fr) 1999-03-10

Family

ID=8166212

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96914152A Withdrawn EP0900202A1 (fr) 1996-04-30 1996-04-30 Esters d'amide de 3-alcoxypyridine-2-acide carboxylique, leur preparation et leur utilisation comme medicaments

Country Status (7)

Country Link
EP (1) EP0900202A1 (fr)
JP (1) JP2000509047A (fr)
KR (1) KR20000065090A (fr)
AU (1) AU5762896A (fr)
CA (1) CA2253282A1 (fr)
NO (1) NO984878L (fr)
WO (1) WO1997041103A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
JP4590157B2 (ja) * 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
DK2298301T3 (en) * 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PL3357911T3 (pl) 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
RS54010B1 (sr) 2009-11-06 2015-10-30 Aerpio Therapeutics Inc. Inhibitori prolil hidroksilaze
WO2012170439A1 (fr) 2011-06-06 2012-12-13 The Ohio State University Procédés de stabilisation d'un facteur 2-alpha induit par l'hypoxie en tant que méthode de traitement du cancer
NO2686520T3 (fr) 2011-06-06 2018-03-17
EP2938191B1 (fr) 2012-12-28 2018-01-31 Dow AgroSciences LLC Mélanges fongicides synergiques destinés au contrôle d'infection fongique dans les céréales
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US20170290333A1 (en) 2014-12-30 2017-10-12 Dow Agrosciences Llc Picolinamide compounds with fungicidal activity
MX2017008444A (es) 2014-12-30 2017-10-02 Dow Agrosciences Llc Picolinamidas como fungicidas.
EP3240408B1 (fr) * 2014-12-30 2020-04-08 Dow Agrosciences LLC Picolinamides présentant une activité fongicide
MX2017008439A (es) * 2014-12-30 2017-10-02 Dow Agrosciences Llc Compuestos de picolinamida con actividad fungicida.
AU2015374459A1 (en) 2014-12-30 2017-06-29 Dow Agrosciences Llc Picolinamide compounds with fungicidal activity
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
EP4667059A3 (fr) * 2015-05-28 2026-04-08 Japan Tobacco Inc. Procédé de traitement ou de prévention de la néphropathie diabétique
TW201842851A (zh) 2017-05-02 2018-12-16 美商陶氏農業科學公司 用於穀類中的真菌防治之協同性混合物
TWI774761B (zh) 2017-05-02 2022-08-21 美商科迪華農業科技有限責任公司 用於穀物中的真菌防治之協同性混合物
US11191269B2 (en) 2017-05-02 2021-12-07 Dow Agrosciences Llc Use of an acyclic picolinamide compound as a fungicide for fungal diseases on turfgrasses
BR102019004480B1 (pt) 2018-03-08 2023-03-28 Dow Agrosciences Llc Picolinamidas como fungicidas
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
KR20210076072A (ko) 2018-10-15 2021-06-23 코르테바 애그리사이언스 엘엘씨 옥시피콜린아미드의 합성 방법
CN114554848A (zh) 2019-10-18 2022-05-27 科迪华农业科技有限责任公司 用于合成吡啶酰胺的方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021117767A1 (fr) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 Procédé de production d'un dérivé d'acide hétéroarylcarboxamide acétique contenant de l'azote

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE149485T1 (de) * 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9741103A1 *

Also Published As

Publication number Publication date
NO984878D0 (no) 1998-10-19
WO1997041103A1 (fr) 1997-11-06
NO984878L (no) 1998-12-29
CA2253282A1 (fr) 1997-11-06
AU5762896A (en) 1997-11-19
JP2000509047A (ja) 2000-07-18
KR20000065090A (ko) 2000-11-06

Similar Documents

Publication Publication Date Title
EP0846685B1 (fr) Esters amides d'acide-2-carboxylique du 3-Hydroxpyridine, leur préparation et leur utilisation comme médicaments
EP0900202A1 (fr) Esters d'amide de 3-alcoxypyridine-2-acide carboxylique, leur preparation et leur utilisation comme medicaments
EP0661269B1 (fr) Amides d'acide carboxylique hétérocycliques substitués leur préparation et leur utilisation comme médicaments
EP0911340B1 (fr) Amides de l'acide 3-isoquinoléique substitués, leur préparation et leur utilisation médicale
EP0650960B1 (fr) Esters de carboxamide hétérocycliques substitués, leur préparation et leur utilisation comme médicaments
EP0562512B1 (fr) Sulfonamidocarbonylpyridine-2-carboxamides et leur utilisation comme médicaments
DE69824037T2 (de) Beta-alanin-derivate als zell-adhäsions-inhibitoren
EP0650961B1 (fr) Amides d'acide carboxylique hétérocycliques substitués, leur preparation et leur utilisation comme médicaments
EP0765871B1 (fr) Dérivés de quinoline-2-carboxamide, leur préparation et leur utilisation comme inhibiteur de la prolyl-4-hydroxylase
DE69833654T2 (de) Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
EP0673932B1 (fr) Sulfonamidocarbonyl-pyridine-2-carboxamides ainsi que leurs pyridine-N-oxydes, procédé pour leur préparation et leur utilisation comme médicaments
CZ458390A3 (en) Diamides of pyrimidine-4,6-dicarboxylic acid, process of their preparation and medicaments based thereon
EP0463592A1 (fr) N-oxyde-pyridines 2,4- et 2,5-substituées, procédés pour leurs préparation et leur utilisation
US4880819A (en) 4-aminopyridine derivatives for improving impaired brain function
EP0278454B1 (fr) Dérivés d'acide pyridine-2,4- et 2,5-dicarboxyliques, leur procédé de préparation, leur utilisation et médicaments à base de ces composés
EP0228625B1 (fr) Dérivés peptidiques à activité inhibitrice vis-à-vis des enzymes hydroxylants, leur procédé de préparation, les agents les contenant et leur emploi
EP1483285A1 (fr) INHIBITEURS DU FACTEUR DE COAGULATION Xa, LEUR PRODUCTION ET LEUR UTILISATION
DD228547A5 (de) Verfahren zur herstellung von neuen amid-verbindungen
DE69626846T2 (de) Phosphonsäurederivate mit metallopeptidase inhibierender aktivität
HUP9903414A2 (en) 3-alkoxypyridine-2-carboxylic acid amide esters,their preparation and their use as drugs
MXPA97009438A (es) Ester-amidas de acido 3-hidroxi-piridina-2-carboxilico, su preparacion y su utilizacion como medicamentos
DE19504226A1 (de) Substituierte Chinoxaline, ihre Herstellung und ihre Verwendung als Arzneimittel
DE4434288A1 (de) Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE4337270A1 (de) Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE2064113A1 (de) Neue Tuberkulostatisch wirkende N1N Diacylhydrazinderivate und Verfahren zur Herstellung derselben

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19990331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19990929